Loading
Necitumumab (Portrazza) is an antibody added to gemcitabine and cisplatin as first treatment for squamous non-small cell lung cancer that has spread; the benefit is modest and it is little used.
Necitumumab was approved by the FDA in November 2015 in combination with gemcitabine and cisplatin for first-line metastatic squamous NSCLC, on the SQUIRE trial (1,093 patients) in which adding the antibody produced a small but statistically significant gain in overall survival, while the INSPIRE trial in non-squamous disease was stopped for lack of benefit and excess thromboembolic deaths. The EU authorised Portrazza in 2016 for EGFR-expressing squamous NSCLC. Cardiopulmonary arrest and hypomagnesaemia carry boxed warnings; rash is universal. Immunotherapy-chemotherapy combinations (KEYNOTE-407) have since made it largely obsolete, and it is listed by the NCCN only as an option in selected patients.
Backbone ribbon from PDB 3B2U. RCSB PDB 3B2U. The ribbon widens where the chain is folded into a regular pattern and narrows where it is a loose loop.
Fully human IgG1 that binds the EGFR ligand-binding domain, blocking ligand-induced activation and downstream MAPK and PI3K signalling. Connects to EGFR.
1.Necitumumab binds EGFR.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 2015 | First-line metastatic squamous NSCLC with gemcitabine and cisplatin |
| EU | 2016 | EGFR-expressing locally advanced or metastatic squamous NSCLC with gemcitabine and cisplatin |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Necitumumab" OR ABSTRACT:"Necitumumab" OR TITLE:"Portrazza" OR ABSTRACT:"Portrazza") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Necitumumab, not a curated reading list.
Shares Squamous cell carcinoma of the lung, Eli Lilly (incl. Loxo), Monoclonal antibodies, Non-small-cell lung cancer.
Shares Lung cancer: the failed and stopped programmes, and why, Gemcitabine + cisplatin, Non-small-cell lung cancer.
Shares Lung cancer: the failed and stopped programmes, and why, Squamous cell carcinoma of the lung, Non-small-cell lung cancer.
Shares Squamous cell carcinoma of the lung, EGFR, Non-small-cell lung cancer.
Shares Lung cancer: the failed and stopped programmes, and why, EGFR, Non-small-cell lung cancer.
Shares Lung cancer: the failed and stopped programmes, and why, Gemcitabine + cisplatin, Non-small-cell lung cancer.
Shares Cetuximab, Monoclonal antibodies.
Shares SQUIRE, Squamous cell carcinoma of the lung, Non-small-cell lung cancer.